

## A VERY SEVERE DERMOPATHY AND OPHTHALMOPATHY IN PATIENTS WITH AUTOIMMUNE THYROID DISEASE: CASE REPORT AND LITERATURE REVIEW

Sema YARMAN, Gönenc KOCABAY\*

### SUMMARY

Although ophthalmopathy (most commonly) and dermopathy (uncommon) are the extrathyroidal manifestations of Graves' disease, they are extremely rare in Hashimoto's thyroiditis. We present a case of Hashimoto's hypothyroidism with ophthalmopathy and dermopathy (the elephantiasic form of pretibial myxedema) in a 46-year-old man. He was diagnosed as having Hashimoto's hypothyroidism with decreased thyroid hormone levels and elevated TSH, anti-thyroid peroxidase and antithyroglobulin antibodies levels, and on palpation the thyroid gland was typical for Hashimoto's thyroiditis. The patient had infiltrative ophthalmopathy and elephantiasic form of pretibial myxedema. Thyroid ultrasound revealed that the parenchyma was heterogenous. Urinary glycosaminoglycans level was increased. Orbital CT scanning showed that extraocular muscles were thickened indicating the infiltrative ophthalmopathy. This case demonstrates the uncommon extrathyroidal manifestation (a very severe dermopathy and ophthalmopathy) of autoimmune thyroid disease.

**Key words:** Autoimmune thyroiditis, ophthalmopathy, dermopathy

### INTRODUCTION

The ophthalmopathy is most commonly associated (80%) with Graves' disease, it can be seen in 10% to 15% of Hashimoto's thyroiditis (1). Besides this finding, pretibial myxedema is a late and an uncommon (10% to 12%) manifestation of Graves' disease (GD) with ophthalmopathy. However both manifestations are very rare only in Hashimoto's thyroiditis (2,3). The very rare association between extrathyroidal manifestations of autoimmune thyroid disease and Hashimoto's thyroiditis is discussed.

### CASE REPORT

In 2002, a 45 year-old-man was admitted with the complaints of weight gain, facial puffiness, and prominence of eye balls continuing for about few months. At that time, he had thyroid ophthalmopathy (grade 3) and pretibial myxedema (nonpitting edema ac-

companied by typical color changes and plaque of the skin, Figure 1), but he was clinically euthyroid. There were no symptoms of hyperthyroidism in the patient's history. Serum thyroid-stimulating hormone (TSH) level was normal (1.1 mU/l, reference range 0.4-4.0), and thyrotropin receptor antibodies (TSH-RAb) were elevated (>405 U/l, reference range 9-14). He has skipped his controls for a year. When he was reexamined, the patient was hypothyroid. He had worsening of his voice and the skin over his tibial areas was changed. He had gained more weight, had cold intolerance and progression of ophthalmopathy. The patient was clinically hypothyroid, and he had severe thyroid ophthalmopathy (Figure 2). Physical examination revealed a pulse of 78/min regular, blood pressure of 130/90 mmHg. There was no appreciable thyromegaly or nodularity in the thyroid gland. Thyroid ultrasound revealed that parenchyma was heterogenous.

Received for publication: September 02, 2003

\* Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Endocrinology and Metabolism, Çapa, Istanbul, Turkey.


Figure 1. Bilateral erythematous infiltrative plaques in the pretibial areas of the lower extremity and foot, at the first admission.



Eye examination showed bilateral proptosis measuring 32 mm Hertel. Lateral eyeball

movement was restricted and convergence was markedly affected (grade 4 ophthalmopathy). He had elephantiac form of dermopathy at lower extremities (Figure 3). A complete blood cell count showed hypochromic microcytic anaemia with normal blood iron and total iron-binding capacity. Thalassaemia minor was present which was proved by peripheral blood smear and hemoglobin electrophoresis. Serum triiodothyronine ( $T_3$ ), thyroxine ( $T_4$ ) and free  $T_4$  levels were decreased with elevated TSH level (0.4 nmol/l, reference range 0.8-2.0; 44 nmol/l, reference range 64-142; 6.8 pmol/l, reference range 12-22; 58 mU/l, reference range 0.2-4.5, respectively). TSH-R, antithyroid peroxidase and antithyroglobulin antibodies were elevated (>405 U/l, reference range 9-14; 3000 U/ml, reference range 0-35; 1870 U/ml, reference range < 60, and respectively). Urinary glycosaminoglycans level was increased (4,29 mg/ml creatinin daily, reference range 0.6-2.6). Computed tomography scan of orbit revealed marked extraocular muscle thickening (Figure 4). On the basis of these findings, hypothyroidism with ophthalmopathy and dermopathy was diagnosed, and replacement therapy with  $T_4$  was started. The patient was discharged after 20

Figure 2. Photograph of the patient showing changes of infiltrative ophthalmopathy



**Figure 3.** The elephantiasic form of PTM, the lesions were coalesce to give the entire extremity an enlarged, verruciform appearance.




days under T<sub>4</sub> replacement (200 µg daily). We decided that ophthalmopathy and dermatopathy treatments modalities will be considered after euthyroidism was achieved.

## DISCUSSION

Autoimmune thyroid disease encompasses a spectrum of thyroid disorders with GD at one end and Hashimoto's thyroiditis at the other end (4). Although GO is mostly associated with hyperthyroidism, ophthalmopathy may less frequently occur also in patients with noncurrent or past evidence of thyroid hyper- or hypofunction (5,6). We here report a case of Hashimoto's hypothyroidism with ophthalmopathy. Brownlie et al. (7) reported that the prevalence of ophthalmopathy associated with Hashimoto's thyroiditis was only 2%, which is a very rare association than with GD. About 15% of patients with severe Graves' ophthalmopathy have the cutaneous manifestation, and 0.5-4.3% of patients with a history of thyrotoxicosis have thyroid dermatopathy has been reported (5,8-10). In the literature, only two case reports of Hashimoto's thyroiditis with ophthalmopathy and dermatopathy have been reported (11,12). On the first admission, the patient had significant eye disease and dermatopathy. The milder form of dermatopathy had progressed to elephantiasic form, and spontaneous hypothyroidism had developed in this case.

**Figure 4.** Computed tomography scan showing bilateral extraocular (inferior rectus) muscle hypernophy.



Schwartz et al.<sup>(13)</sup> reported that the most prevalent form of dermatopathy associated with GD was nonpitting edema (43.3%), and the elephantiac form was found only 2.8%. In another review of 150 cases of dermatopathy, the elephantiac form occurred in only one patient<sup>(14)</sup>. Our patient had this rare form of dermatopathy.

Presence of ophthalmopathy and dermatopathy in Hashimoto's thyroiditis can be explained on the basis of sharing of antigens of thyroid (thyroid peroxidase, TPO) with orbital and dermal fibroblast. Circulating TSH-RAb activity was increased, while anti-TPO was elevated in this case. Wyse et al.<sup>(15)</sup> reported that TSH-RAb are also expressed in Hashimoto's thyroiditis. So, they suggested that the effect of TSH-RAb on orbital and dermal tissue remains uninhibited, resulting in development of orbitopathy and dermatopathy. On the other hand, Cronin et al.<sup>(11)</sup> reported a similar case of Hashimoto's thyroiditis with ophthalmopathy and pretibial myxedema, and they have also proposed that the TSH-RAb of GD which was raised in their case was ineffective in producing hyperthyroidism because of thyroid destruction due to Hashimoto's thyroiditis. Alternatively, hypothyroidism could have resulted from the effects of a circulating TSH-R blocking antibody. This case may be a Graves' disease which spontaneously culminated in Hashimoto's thyroiditis and hypothyroidism, but his medical history revealed that he had no any symptoms of hyperthyroidism. So, the association of elevated TSH-RAb levels and hypothyroidism can be explained as reported by Cronin et al.<sup>(11)</sup>. Yet it will be more correct to name it as severe dermatopathy and orbitopathy with autoimmune thyroid disease. Because the histopathology of the thyroid is not available to make a precise distinction between GD and Hashimoto's thyroiditis.

On the otherhand, there was no concomitant occurrence of Hashimoto's hypothyroidism

and Thalessemia, as seen in our patient. Thus, this combination may be completely coincidental, since both disease are not rare in our country.

As a result, we here report a very severe dermatopathy and ophthalmopathy associated with autoimmune thyroid disease.

## REFERENCES

1. Bahn RS, Garrity JA, Bartley GB, Gorman CA. Diagnostic evaluation of Graves' ophthalmopathy. *Endocrinol Metab Clin North Am* 1988; 17:527-545.
2. Fatourehchi V, Pajouhi M & Fransway AF. Dermopathy of Graves' disease (pretibial myxedema): review of 150 cases. *Medicine* 1994; 73:1-7.
3. Horiuchi Y. Pretibial myxedema associated with chronic thyroiditis. *Arch Dermatol* 1985; 121:451.
4. Fisher DA, Pandian MR, Carlton E. Autoimmune thyroid disease: an expanding spectrum. *Pediatr Clin North Am* 1987; 34:907-918.
5. Burch HB, Wartofsky L. Graves' ophthalmopathy: current concepts regarding pathogenesis and management. *Endocrinol Rev* 1993; 14:747-793.
6. Marcocci C, Bartalena L, Bogazzi F, Panicucci M, Pinchera A. Studies on the occurrence of ophthalmopathy in Graves' disease. *Acta Endocrinol* 1989; 120:473-478.
7. Brownlie BE, Newton OA, Singh SP. Ophthalmopathy associated with primary hypothyroidism. *Acta Endocrinol* 1975; 79:691-699.
8. Kriss JP. Pathogenesis and treatment of pretibial myxedema. *Endocrinol Metab Clin North Am* 1987; 16:409-415.
9. Kahaly G, Schuiler M, Sewell AC, et al. Urinary glycosaminoglycans in Graves' ophthalmopathy. *Clinical Endocrinology* 1990; 33:35-44.
10. Schwartz KM, Fatourehchi V, Ahmed DDF, Gregory RP. Dermopathy of Graves' disease (pretibial myxedema): long-term outcome. *J Clin Endocrinol Metab* 2002; 87:435-446.
11. Cronin CC, Higgins TM, Murphy Ferriss JB. Concomitant Graves' disease and Hashimoto's thyroiditis, presenting as primary hypothyroidism. *Ir Med J* 1996; 89:141-142.
12. Singh SK, Singh KK, Sahay RK. Hashimoto's Thyroiditis with Orbitopathy and Dermopathy. *J Postgraduate Medicine "Images in Medicine"* 2000; 46 (4).
13. Schwartz KM, Fatourehchi V, Ahmed DDF, Pond GR. Dermopathy of Graves' Disease (Pretibial Myxedema): Long-Term Outcome. *J Clin Endocrinol Metab* 2002; 87:438-446.
14. Fatourehchi V, Pajouhi M, Fransway AF. Dermopathy of Graves' disease (pretibial myxedema). Review of 150 cases. *Medicine* 1994; 73:1-7.
15. Wyse EP, McConahey WM, Woolner LB, Scholz DA, Kearns TP. Ophthalmopathy without hyperthyroidism in patients with histological Hashimoto's thyroiditis. *J Clin Endocrinol Metab* 1968; 28:1623-1629.